What’s Happening
Chatter
- FDA Lends a Single Arm: Papzimeos Approval Highlights FDA’s Willingness to Rely on Single-Arm Trials for Rare Diseases
- I’ve got the Research Plus, Reference 2, AND the Bioreactor light saber
- electronic lab notes
- More doodles of different cells
- Is there more money in Manufacturing?
- Why is receiving portal access so hard?
- Transition from Botany to Biotechnology
- Blueprint for an engineered macrophage-based sentinel cell (CK4–) for early threat detection and graded immune response
- Pivoting from Regulatory Affairs to Medical Device Sales — Advice Needed
- UK-Based training courses
- RFK is SUCH a bad pick that he alone will just lay waste to the entire country for the next 3.5 years
- Looking for advice on my CV
- IQVIA competency interview CRA
- Is Sanofi leaving ICON for Syneos?
- Do you ever think what we do is messed up?
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…